共 140 条
[71]
Karavellas M.P., Plummer D.J., Macdonald J.C., Et al., Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy, J. Infect. Dis., 179, pp. 697-700, (1999)
[72]
Deayton J.R., Wilson P., Sabin C.A., Et al., Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy, AIDS, 14, pp. 1163-1170, (2000)
[73]
Nguyen Q.D., Kempen J.H., Bolton S.G., Et al., Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy, Am. J. Ophthalmol., 129, pp. 634-639, (2000)
[74]
Stone S.F., Price P., Tay-Kearney M.L., French M.A., Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment, J. Infect. Dis., 185, pp. 1813-1817, (2002)
[75]
Karavellas M.P., Song M., Macdonald J.C., Freeman W.R., Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis, Am. J. Ophthalmol., 130, pp. 57-64, (2000)
[76]
Zegans M.E., Walton R.C., Holland G.N., Et al., Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis, Am. J. Ophthalmol., 125, pp. 292-300, (1998)
[77]
Sanislo S.R., Lowder C.Y., Kaiser P.K., Optic nerve head neovascularization in a patient with inactive cytomegalovirus retinitis and immune recovery, Am. J. Ophthalmol., 126, pp. 318-320, (1998)
[78]
Boyraz-Ikiz H.D., Witmer J.P., Frissen P.H., Cytomegalovirus (re)activation plays no role in the ocular vitritis observed after initiation of highly active antiretroviral therapy, AIDS, 13, (1999)
[79]
Miller R.F., Shaw P.J., Williams I.G., Immune reconstitution CMV pneumonitis, Sex. Transm. Infect., 76, (2000)
[80]
Whitcup S.M., Cytomegalovirus retinitis in the era of highly active antiretroviral therapy, JAMA, 283, pp. 653-657, (2000)